Increased Capital Boosts Biotech R&D Job Postings, Employment
Biotech R&D job postings on BioSpace jumped 21% year‑over‑year in April, marking the longest month‑over‑month rise since mid‑2024. A CBRE report shows biotech employment reached a record 295,600 in February after five consecutive months of growth, the longest streak since early 2023. The surge is linked to a revitalized capital market, with follow‑on offerings and IPOs accelerating for smaller‑cap biotechs throughout 2025. Companies such as AbbVie, Amgen and Eli Lilly now list nearly 400 open R&D positions.
Artera Secures FDA Clearance for AI-Based Breast Cancer Risk Tool
The U.S. Food and Drug Administration granted clearance to ArteraAI Breast, an AI‑driven digital pathology tool that combines digitized histopathology slides with clinical data to generate a risk score for distant metastasis in early‑stage hormone‑receptor‑positive/HER2‑negative breast cancer. The system stratifies...
Oncology Care Ignores Patient Survival vs QoL Preferences
"Patient preference for extending survival or maintaining QoL was not associated with up-front treatment modifications or downstream outcomes, suggesting a possible lack of responsiveness of the current oncology care delivery system to patient preference." https://t.co/0RXf4h2dr3 In: Outcomes of Older Adults With Advanced...
Immortal Dragons: The Quest to ‘Make Death Optional’
Immortal Dragons, a Singapore‑based longevity fund founded by 34‑year‑old CEO Boyang Wang, secured $40 million—$4 million from friends and family and $36 million of Wang’s own money—to back moonshot biotech projects. The fund’s portfolio includes Frontier Bio, which is developing 3D bio‑fabrication techniques...
WA Biotech Duo Takes Aim at Diabetes Beyond Ozempic
Australian biotech duo ProGenis Pharmaceuticals and Syngenis Labs are developing RNA‑based antisense therapies that target insulin resistance, a root cause of type‑2 diabetes, to complement GLP‑1 drugs. Syngenis is building Australia’s first GMP‑grade synthetic DNA/RNA manufacturing facility, expected to be...
Japan's TMS-007 Shows Promise for Stroke Treatment
@ej23ny @BiotechXGuru @biotech_cash @Ceazar_Black Anyone here look at Japan Biotech? I'm far from an expert, but I think 4891.T (TMS) is worth looking into. Its a nano cap with dilutive equity warrants (and a smallish cash runway) but their main...
The Latest News in Vaccine Obstruction
Large-scale safety studies of COVID‑19 and shingles vaccines, analyzing millions of records, found rare serious side effects, but the FDA blocked their publication citing unsupported conclusions. The agency also refused to file Moderna’s mRNA flu‑COVID combo vaccine, despite European approval...
PYC Therapeutics Advances PKD Program with Phase 1b Multiple Ascending Dose Study Initiation
PYC Therapeutics has dosed the first patient in a Phase 1b multiple‑ascending‑dose (MAD) study of its PKD candidate PYC‑003, targeting safety, tolerability and early efficacy signals such as urinary PC1 protein, total kidney volume and eGFR. Results from the earlier Phase 1a...
Unfunded $24B Could Have Delivered 100‑Day Prototype Vaccines
Every so often I think about how, in 2022, for $24B we could had "prototype vaccines ready for each of the 26 known viral families that cause human disease" so they can be deployed in 100 days if there was...
The Peptide Problem: Hype Is Outrunning the Evidence
Health Canada has warned Canadians against buying and injecting unauthorized peptide products such as BPC‑157, CJC‑1295, ipamorelin, TB‑500 and retatrutide, and has already seized several shipments. Influencers on Instagram and TikTok are promoting these compounds for anti‑aging, weight loss and...
Hoth Therapeutics Gains First European Clearance for HT-001 Oncology Trial in Spain
Hoth Therapeutics announced that Spain’s health authority has granted authorization for its Phase 2a CLEER trial of HT-001, a therapy aimed at reducing EGFR‑inhibitor skin toxicities. Interim results show meaningful efficacy and safety, paving the way for broader European patient enrollment.
Bayer to Acquire Perfuse Therapeutics, Expanding Its Ophthalmology Portfolio
Bayer disclosed plans to acquire biotech firm Perfuse Therapeutics, aiming to strengthen its ophthalmology pipeline. The deal, announced through Bayer’s newsroom, comes without disclosed financial terms but signals a strategic push into eye‑care. The acquisition could accelerate Bayer’s development of...
Gilead’s Yeztugo Sees 9,000 Q1 Prescriptions Yet Faces Insurance Hurdles
Gilead Sciences' long‑acting HIV pre‑exposure prophylaxis, Yeztugo, logged more than 9,000 prescriptions in Q1 2024, but clinicians say uptake is uneven. Insurers’ reliance on medical‑benefit billing and a $14,000‑plus price tag create out‑of‑pocket costs that deter many patients.
Spinogenix Secures FDA Fast Track for ALS Drug Tazbentetol
Spinogenix announced that the U.S. FDA granted Fast Track designation to its oral ALS candidate tazbentetol, accelerating development after Phase 2a data showed 82% of patients stabilized or improved and a 76% slower decline versus historical controls.
Akebia Therapeutics Inc (AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics reported 2025 total revenue of $236.2 million, a 47% increase year‑over‑year, driven by the commercial launch of its oral HIF‑PH inhibitor Vafseo and higher sales of the phosphate binder Auryxia. Vafseo now reaches 290,000 dialysis patients across 24 organizations,...
Monte Rosa Therapeutics Inc (GLUE) Q1 2026 Earnings Call Transcript
Monte Rosa Therapeutics reported Q1 2026 worldwide revenue of $141.2 million, a 14.3% year‑over‑year increase, driven primarily by strong U.S. sales of its AtriClip and Cryosphere product lines. Adjusted EBITDA rose to $17 million, nearly doubling the prior‑year quarter, while gross margin...
Ironwood Pharmaceuticals Inc (IRWD) Q1 2026 Earnings Call Transcript
Ironwood Pharmaceuticals reported 2025 LINZESS U.S. net sales of $865 million, matching guidance despite a 6% price erosion tied to Medicare Part D changes. Prescription demand grew 11% for the second year, maintaining a 45% market share in the IBS‑C and chronic...
There Is No Vaccine for Deadly Hantavirus: What that Means for Future Outbreaks
An outbreak of Andes hantavirus on the cruise ship MV Hondius left three confirmed cases and three deaths, highlighting the deadly potential of the rodent‑borne virus. The World Health Organization confirmed the strain has no approved treatments or vaccines. Virologist...
NewAmsterdam Pharma Company NV (NAMS) Q1 2026 Earnings Call Transcript
NewAmsterdam Pharma reported Q1 2026 net revenue of $45.1 million, up from $42 million a year earlier, while cash rose to $308 million and the company remains debt‑free. U.S. VASCEPA captured 48% of the IPE market, a 6‑point gain, and branded prescriptions grew...
Lantheus Holdings Inc (LNTH) Q1 2026 Earnings Call Transcript
Lantheus Holdings reported Q1 2026 revenue of $377.3 million, a 1.2% year‑over‑year increase and 8.6% when excluding divested SPEC revenue. Oncology sales from PYLARIFY fell 6.5% despite a 5.8% volume rise, while cardiology product DEFINITY grew 6.8% and retained over 80%...
PTC Therapeutics Inc (PTCT) Q1 2026 Earnings Call Transcript
PTC Therapeutics reported record Q1 2026 product revenue of $226 million, driven by a $125 million Sephience launch that grew 36% quarter‑over‑quarter. The company lifted full‑year product revenue guidance to $750‑$850 million and total revenue to $1.08‑$1.18 billion, citing strong U.S. uptake, the first...
INmune Bio Inc (INMB) Q1 2026 Earnings Call Transcript
INmune Bio reported Q1 2026 results showing a cash balance of $21.4 million, sufficient to sustain operations through Q1 2027, and a narrowed net loss of $5.4 million. The company highlighted significant progress on its CORDStrom platform, including approval of the U.K. Pediatric Investigation...
Guardant Health Inc (GH) Q1 2026 Earnings Call Transcript
Guardant Health reported Q1 2026 revenue of $302 million, a 48% year‑over‑year increase and the fastest annual growth in five years. Oncology revenue rose 36% to $205 million, driven by 86,000 tests—a 47% volume jump—while its Shield screening test generated $42 million from...
Zymeworks Inc (ZYME) Q1 2026 Earnings Call Transcript
Zymeworks reported a PDUFA deadline of August 25, 2026 for its zanidatumab HER2‑positive gastroesophageal adenocarcinoma (GEA) indication, with a supplemental BLA filed in China. The company stands to receive up to $265 million in milestone payments contingent on U.S. and Chinese...
Delcath Systems Inc (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems reported Q1 2026 revenue of $25 million, a 26% increase year‑over‑year, driven primarily by $23.3 million from its HEPZATO kit. The company recorded a net loss of $1.1 million but posted adjusted EBITDA of $3.4 million and reaffirmed a 2026 revenue target...
Absci Corp (ABSI) Q1 2026 Earnings Call Transcript
Absci Corp (ABSI) reported Q1 2026 revenue of $200 K while R&D expenses rose to $19.3 M as the company advances its lead prolactin‑receptor antibody ABS‑201. The Phase 1/2a androgenic alopecia trial is on track, with safety data due next month and interim...
Harmony Biosciences Holdings Inc (HRMY) Q1 2026 Earnings Call Transcript
Harmony Biosciences reported record Q1 product revenue of $243.8 million, a 21% increase year‑over‑year, driven by sustained demand for its Wakix sleep‑wake therapy. The company added roughly 400 patients per quarter, reaching about 8,500 on Wakix, and reaffirmed 2026 revenue guidance...
Lexicon Pharmaceuticals Inc (LXRX) Q1 2026 Earnings Call Transcript
Lexicon Pharmaceuticals reported Q1 2026 revenue of $5.5 million, largely from a $4.3 million Novo Nordisk licensing deal and INPEFA sales. The company cut its quarterly net loss to $15.5 million and reduced annual operating expenses by $129.5 million, boosting cash to $125 million after...
Crinetics Pharmaceuticals Inc (CRNX) Q1 2026 Earnings Call Transcript
Crinetics reported $10.3 million net product revenue from Palsonify in Q1 2026, driven by 232 new patient enrollments and a prescriber base that grew to 263 unique physicians. Treatment‑naive patients rose to 15 % of enrollments, indicating expanding first‑line use. Reimbursement coverage...
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals reported accelerating uptake of its newly launched triglyceride‑lowering therapy REDEMPLO, surpassing 400 prescriptions with a 40% surge in the last month. The company announced a price reduction to $45,000 per patient per year and secured payer policies that...
Scholar Rock Holding Corp (SRRK) Q1 2026 Earnings Call Transcript
Scholar Rock Holding Corp reported $368 million in cash and secured a $550 million debt facility, providing ample liquidity for 2026 initiatives. The FDA completed a reinspection of the Catalent Indiana site with no further requests, clearing the path for an imminent...
Organogenesis Holdings Inc (ORGO) Q1 2026 Earnings Call Transcript
Organogenesis Holdings reported a 58% drop in Q1 net product revenue to $36.3 million, driven primarily by a 63% plunge in advanced wound‑care sales after CMS reimbursement policy changes created clinician confusion. The company recorded a GAAP operating loss of...
SIGA Technologies Inc (SIGA) Q1 2026 Earnings Call Transcript
SIGA Technologies reported Q1 2026 revenue of roughly $6 million, a pretax loss of $5 million and a cash balance of $146 million with no debt. The company announced a $13 million oral TPOXX order for an Asia‑Pacific customer in Q2 and sealed an...
Insmed Inc (INSM) Q1 2026 Earnings Call Transcript
Insmed reported that its newly launched Brinsupri generated $144.6 million in its first full quarter and now projects at least $1 billion in U.S. revenue for 2026. The company highlighted strong early adoption, with over 11,500 new patients in 2025, 90%+ payer...
Science Spotlight: New Prime Editing Tools for Large DNA Insertions
BioCentury’s website employs a tiered cookie framework that classifies cookies into strictly necessary, functional, marketing, advertising, and analytics groups. Strictly necessary cookies power core services such as authentication, registration, and user‑preference management, while functional cookies enhance site personalization. Marketing and...
AI Speeds Dangerous Bio Design; Economics Drive Safety Race‑to‑bottom
"What keeps me up at night is the fast pace of acceleration of open weight models in the ecosystem. They do not prioritize the same type of safety refusals." - Yunyun Wang, @OpenAI We just ran a biosecurity panel at...
From Discovery to GMP: Building Scalable Cell Therapy Manufacturing
Genetic Engineering & Biotechnology News and ElevateBio released an eBook titled “From Discovery to GMP: Building Scalable Cell Therapy Manufacturing.” It argues that the next growth phase for cell and gene therapies hinges on integrating therapeutic design with manufacturing to...
Membrane Complex Aids Rock-Eating Microbes in Converting Carbon Dioxide to Biomass
Researchers at the Universities of Potsdam and Marburg have detailed the structure of the DAB2 membrane complex in the sulfur bacterium Halothiobacillus neapolitanus. The complex enables lithoautotrophic microbes to convert CO₂ directly into bicarbonate (HCO₃⁻) using the cell’s membrane potential,...
An Essential Framework to Navigating Technical Challenges in Contemporary OSD Development
Oral solid dosage (OSD) development faces mounting technical hurdles as biopharma pipelines become richer in poorly soluble compounds, with 70‑90% of new small‑molecule candidates classified as BCS Class II or IV. Early‑risk identification—through comprehensive physicochemical profiling, excipient compatibility testing, and Quality...
First Human Trials Aim to Rejuvenate Immune System by Regenerating the Thymus
The TRIIM‑X trial has begun enrolling participants to test a thymus‑regeneration therapy that could reverse immune aging. Researchers hope the intervention will restore T‑cell production and improve resilience against infection and cancer, marking a shift from measuring immune decline to...
Inflammatory Genes Link Obesity, Diabetes to Pancreatic Cancer
Shared inflammatory genes are active in both pancreatic cancer and metabolic diseases like obesity and diabetes, providing insight into why metabolic conditions worsen cancer outcomes and highlighting potential targets for improved prediction and treatment. cancerbiology
MRNA Flu Shot Cuts Illness in 50+, Raises Reactogenicity
Prasad wanted high-dose flu vaccine comparator - hence the original Refusal-to-File. FDA then agreed to a split application for over-65's and under, and accepted the revised application.
Nanobiotix Secures FDA Acceptance of Protocol Amendment to Accelerate Phase 3 NANORAY-312 Trial
Nanobiotix announced that the U.S. FDA has accepted a protocol amendment for its Phase 3 NANORAY‑312 trial, eliminating the interim analysis and moving to a modified final analysis with fewer events. The change is designed to shorten the study timeline for...
SIRT6 Shields Aorta by Cutting Inflammation and Aging
SIRT6 appears protective in aortic disease, as higher levels reduce vascular inflammation and smooth muscle cell aging, thereby helping prevent both aortic aneurysm and dissection progression. https://t.co/eXuKrR7oNF
Even a Dog Loves Scaling Virtual Biology Panel
Not all our #SynBioBeta2026 attendees walk on 2 legs 🐶 Taco here found the "From Cells to Patients: Solving the Scale Mismatch in Virtual Biology" Main Stage Panel particularly interesting. https://t.co/6xMHnozSqd
Merck Completes $5.3 B Purchase of Terns, Adding Oral CML Drug TERN‑701
Merck closed a cash tender offer for Terns Pharmaceuticals at $53 a share, valuing the deal at roughly $5.3 billion. The acquisition brings TERN‑701, an oral BCR‑ABL1 inhibitor with FDA Breakthrough Therapy Designation, into Merck’s oncology pipeline and will be recorded...
First‑in‑class Molecular Glue Shows Breakthrough Pancreatic Cancer Results
We're seeing major advances vs pancreatic cancer. Today @NEJM data for daraxonrasib @RevMedicines https://t.co/IinceclK6w Context for this first-in-class molecular glue https://t.co/IinceclK6w https://t.co/odhmXQqzMF
Quick Turnaround: Good Longevity Trial News Arrives
I post about working around longevity clinical trials and an hour later @j_n_justice tells me good news about longevity clinical trials... 😍
Caris Life Sciences Launches AI Test to Predict Early and Late Breast Cancer Recurrence
Caris Life Sciences introduced Caris MI Clarity, the first AI-driven test that predicts both early and late distant recurrence in postmenopausal HR‑positive/HER2‑negative, node‑negative breast cancer at diagnosis. Results are returned within three business days, promising faster, more comprehensive risk stratification...
Trump Drug Strategy Clashes With New Funding Policies
Trump administration’s drug strategy is at odds with recent actions on funding, policy https://t.co/UDiuVnEMDZ via @statnews